Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
Leuzy, Antoine LU ; Cullen, Nicholas C. LU ; Mattsson-Carlgren, Niklas LU
and Hansson, Oskar
LU
(2021)
In Current Opinion in Neurology
34(2).
p.266-274
- Abstract
PURPOSE OF REVIEW: This review provides a concise overview of recent advances in cerebrospinal fluid (CSF) and blood-based biomarkers of Alzheimer's disease lesions. RECENT FINDINGS: Important recent advances for CSF Alzheimer's disease biomarkers include the introduction of fully automated assays, the development and implementation of certified reference materials for CSF Aβ42 and a unified protocol for handling of samples, which all support reliability and availability of CSF Alzheimer's disease biomarkers. Aβ deposition can be detected using Aβ42/Aβ40 ratio in both CSF and plasma, though a much more modest change is seen in plasma. Tau aggregation can be detected using phosphorylated tau (P-tau) at threonine 181 and 217 in CSF, with... (More)
PURPOSE OF REVIEW: This review provides a concise overview of recent advances in cerebrospinal fluid (CSF) and blood-based biomarkers of Alzheimer's disease lesions. RECENT FINDINGS: Important recent advances for CSF Alzheimer's disease biomarkers include the introduction of fully automated assays, the development and implementation of certified reference materials for CSF Aβ42 and a unified protocol for handling of samples, which all support reliability and availability of CSF Alzheimer's disease biomarkers. Aβ deposition can be detected using Aβ42/Aβ40 ratio in both CSF and plasma, though a much more modest change is seen in plasma. Tau aggregation can be detected using phosphorylated tau (P-tau) at threonine 181 and 217 in CSF, with similar accuracy in plasma. Neurofilament light (NfL) be measured in CSF and shows similar diagnostic accuracy in plasma. Though total tau (T-tau) can also be measured in plasma, this measure is of limited clinical relevance for Alzheimer's disease in its current immunoassay format. SUMMARY: Alzheimer's disease biomarkers, including Aβ, P-tau and NfL can now be reliably measured in both CSF and blood. Plasma-based measures of P-tau show particular promise, with potential applications in both clinical practice and in clinical trials.
(Less)
- author
- Leuzy, Antoine
LU
; Cullen, Nicholas C.
LU
; Mattsson-Carlgren, Niklas
LU
and Hansson, Oskar
LU
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Current Opinion in Neurology
- volume
- 34
- issue
- 2
- pages
- 9 pages
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- scopus:85102657841
- pmid:33470669
- ISSN
- 1473-6551
- DOI
- 10.1097/WCO.0000000000000904
- language
- English
- LU publication?
- yes
- id
- ca7bafdb-8c58-4948-857f-83f2d31b4b79
- date added to LUP
- 2021-03-24 10:11:38
- date last changed
- 2024-04-18 04:13:00
@article{ca7bafdb-8c58-4948-857f-83f2d31b4b79,
abstract = {{<p>PURPOSE OF REVIEW: This review provides a concise overview of recent advances in cerebrospinal fluid (CSF) and blood-based biomarkers of Alzheimer's disease lesions. RECENT FINDINGS: Important recent advances for CSF Alzheimer's disease biomarkers include the introduction of fully automated assays, the development and implementation of certified reference materials for CSF Aβ42 and a unified protocol for handling of samples, which all support reliability and availability of CSF Alzheimer's disease biomarkers. Aβ deposition can be detected using Aβ42/Aβ40 ratio in both CSF and plasma, though a much more modest change is seen in plasma. Tau aggregation can be detected using phosphorylated tau (P-tau) at threonine 181 and 217 in CSF, with similar accuracy in plasma. Neurofilament light (NfL) be measured in CSF and shows similar diagnostic accuracy in plasma. Though total tau (T-tau) can also be measured in plasma, this measure is of limited clinical relevance for Alzheimer's disease in its current immunoassay format. SUMMARY: Alzheimer's disease biomarkers, including Aβ, P-tau and NfL can now be reliably measured in both CSF and blood. Plasma-based measures of P-tau show particular promise, with potential applications in both clinical practice and in clinical trials.</p>}},
author = {{Leuzy, Antoine and Cullen, Nicholas C. and Mattsson-Carlgren, Niklas and Hansson, Oskar}},
issn = {{1473-6551}},
language = {{eng}},
number = {{2}},
pages = {{266--274}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Current Opinion in Neurology}},
title = {{Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease}},
url = {{http://dx.doi.org/10.1097/WCO.0000000000000904}},
doi = {{10.1097/WCO.0000000000000904}},
volume = {{34}},
year = {{2021}},
}